IMMIX BIOPHARMA INC

IMMXNASDAQ

🏆 #2463 by market capEarnings Nov 6US Equity

$11.25▼ $0.24 (−2.09%)

Live

1h▼ 1.7%

24h▼ 2.1%

7d▲ 17.6%

14d▲ 37.9%

30d▲ 7.0%

1y▲ 384.9%

🏦Market Cap

$785M

Small Cap

📈Revenue Growth (YoY)

—

📊Gross Margin

—

💵FCF Margin

—

⚖️P/S Ratio

—

Otter Score

Weak

Trading Snapshot

Day Range: $11.13 – $11.32
52-Week Range: $1.94 – $12.14
Volume: $1.73B
Avg Volume: $2.26B
Shares Outstanding: 69.8M
Next Earnings: Sep 8, 2026

Fundamentals Snapshot

Annual Revenue: $57M
Last Q Revenue: $13M
P/E Ratio: —
P/S Ratio: —
EPS (TTM): $-0.91
Dividend Yield: —

Why Investors Own IMMX

✓High-growth profile — revenue up +17.6% YoY with expanding US Equity exposure.
✓Healthy economics — 67% gross margin and 5% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$57M▲ +20.2% YoY

Gross Margin (TTM)

67.3%▲ +3.5% YoY

Operating Income (TTM)

$10M▲ +20.2% YoY

Free Cash Flow (TTM)

$3M▲ +20.2% YoY

About IMMIX BIOPHARMA INC

Immix Biopharma, Inc. is a clinical-stage biotechnology firm dedicated to creating a range of tissue-specific therapies. Operating in both the United States and Australia, their primary focus areas are oncology (cancer) and inflammatory diseases. Their product pipeline includes IMX-110, which is currently undergoing Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and various solid tumors. They are also developing IMX-111, a targeted biologic agent for colorectal cancers, and IMX-120, another tissue-specific biologic designed to address ulcerative colitis and severe Crohn's disease. In a strategic move, the company has forged a clinical collaboration and supply agreement with BeiGene Ltd. This partnership aims to conduct a Phase 1b combination clinical trial, evaluating IMX-110 in conjunction with BeiGene's anti-PD-1 drug, Tislelizumab, for solid tumor indications. Founded in 2012, Immix Biopharma maintains its headquarters in Los Angeles, California.

🦦